<DOC>
	<DOCNO>NCT00528060</DOCNO>
	<brief_summary>trial assess pharmacokinetics long term plasma exposure follow antiretrovirals : atazanavir combine ritonavir tenofovir/emtricitabine fixed-dose combination . All drug deliver MEMS electronic device monitor dose history .</brief_summary>
	<brief_title>Measure Pharmacokinetic Parameters Adherence With MEMS Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir Truvada</brief_title>
	<detailed_description>The trial phase II , open label , non-randomized , prospective multicenter trial ass pharmacokinetics long term plasma exposure follow antiretrovirals : atazanavir combine ritonavir tenofovir/emtricitabine fixed-dose combination . All drug deliver MEMS electronic device monitor dose history .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Na√Øve treatment HIV 1 infect patient CD4 100/mm3 pregnancy renal failure hepatitic disease ongoing opportunistic disease Hb 8g/dl ; platelet 50 000/mm3 ; neutrophil 750/mm3 ; Prothrombin index 80 % , Ca Ph &gt; 2.5 N drug interact investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>atazanavir</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>